10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Description

This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

Conditions

Atopic Dermatitis

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.

A Prospective 10 Year Observational Registry of Pediatric Subjects (Age Greater Than or Equal to Two Years to Age Less Than or Equal to 17 Years) With Atopic Dermatitis Who Have Used Elidel Cream 1% (Pimecrolimus)

10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus

Condition
Atopic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Registry, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * males and females
  • * greater than or equal to 2 years and less than or equal to 17 years at enrollment
  • * diagnosis of atopic dermatitis (confirmed by treating physician)
  • * applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks
  • * past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease
  • * past or present use of oral immunosuppressive therapy

Ages Eligible for Study

2 Years to 17 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bausch Health Americas, Inc.,

Anya Loncaric, STUDY_DIRECTOR, Bausch Health

Study Record Dates

2026-12